1 Validation of an unbiased metagenomic detection assay for RNA viruses in

2 viral transport media and plasma

- 3 Anthony D. Kappell (0000-0003-3511-9207)*, Kathleen Q. Schulte (0000-0002-0558-0660), Elizabeth
- 4 A. Scheuermann (0000-0002-7498-7130), Matthew B. Scholz (0000-0003-3686-1227), Nicolette C.
- 5 Keplinger, Amanda N. Scholes (0000-0003-4964-6139), Taylor A. Wolt, Viviana M. June (0000-0001-
- 6 5519-4971), Cole J. Schulte, Leah W. Allen, Krista L. Ternus (0000-0003-1138-5308) and F. Curtis
- 7 Hewitt (0000-0001-9546-5625)
- 8 Signature Science, LLC, Austin, Texas, United States of America
- 9 *Corresponding author
- 10
- 11 Corresponding author contact information:
- 12 Anthony D. Kappell
- 13 akappell@signaturescience.com

14 Abstract (250 words)

15 Unbiased long read sequencing holds enormous potential for the detection of pathogen sequences in 16 clinical samples. However, the untargeted nature of these methods precludes conventional PCR 17 approaches, and the metagenomic content of each sample increases the challenge of bioinformatic 18 analysis. Here, we evaluate a previously described novel workflow for unbiased RNA virus sequence 19 identification in a series of contrived and real-world samples. The novel multiplex library preparation workflow was developed for the Oxford Nanopore Technologies (ONT) MinIONTM sequencer using 20 21 reverse transcription, whole genome amplification, and ONT's Ligation Sequencing Kit with Native 22 Barcode Expansion. The workflow includes spiked MS2 Phage as an internal positive control and 23 generates an 8-plex library with 6 samples, a negative control and a *gfp* transcript positive control. 24 Targeted and untargeted data analysis was performed using the EPI2ME Labs framework and open access 25 tools that are readily accessible to most clinical laboratories. Contrived samples composed of common 26 respiratory pathogens (Influenza A, Respiratory Syncytial Virus and Human Coronavirus 229E) in viral 27 transport media (VTM) and bloodborne pathogens (Zika Virus, Hepatitis A Virus, Yellow Fever Virus 28 and Chikungunya Virus) in human plasma were used to establish the limits of detection for this assay. We 29 also evaluated the diagnostic accuracy of the assay using remnant clinical samples and found that it 30 showed 100% specificity and 62.9% clinical sensitivity. More studies are needed to further evaluate 31 pathogen detection and better position thresholds for detection and non-detection in various clinical 32 sample metagenomic mixtures.

33 Keywords (3-10 words)

34 Nanopore Sequencing; MinION; RNA Virus; Agnostic Sequencing; Metagenomics; Respiratory

Pathogens; Blood Pathogens; coronavirus; SARS-CoV-2; COVID-19

36

37 Introduction

38 RNA viruses pose a significant threat to global public health. The prime example of this is the 39 COVID-19 pandemic, but it is far from the only virus that has caused outbreaks in recent years. There are 40 seasonal outbreaks every year of respiratory RNA viruses, such as paramyxoviruses (e.g., respiratory 41 syncytial virus and human metapneumovirus) and alphainfluenzaviruses (e.g., Influenza A). There have 42 also been recurring regional outbreaks of mosquito borne diseases caused by RNA viruses such as 43 alphaviruses (e.g., Chikungunya virus) and flaviviruses (e.g., Zika virus, Dengue virus and Yellow Fever 44 virus). These viruses pose a serious threat to human health – in the United States alone, hundreds of 45 thousands of people are hospitalized each year from complications of respiratory viral infections 46 (Thompson et al. 2004). Respiratory viral illnesses are also associated with a steep economic burden; they 47 are collectively estimated to cost over \$127 billion each year (Fendrick et al. 2003; Young-Xu et al. 48 2017).

49 Unbiased, metagenomic sequence-based approaches could lead to early detection of both 50 previously characterized and novel RNA viruses and serve as a universal assay to detect infectious 51 disease agents (Bibby 2013; Miller et al. 2013; Schlaberg et al. 2017). Established clinical tests largely 52 rely on PCR, culturing or antibody specificity to detect pathogens. These approaches are limited in that 53 they require prior assumptions about the pathogens that might be present. Furthermore, many diagnostic 54 tests rely on culturing the pathogen, which can create delays of several days to diagnosis. Hypothesis-free 55 approaches have the distinct advantage of being able to survey the presence of multiple infectious agents 56 at once in a single assay, which allows pathogens to be identified more quickly and without collecting 57 further samples for a series of tests.

58 Nanopore sequencing is a cost-effective third-generation sequencing method that allows long 59 reads to be generated on a hand-held device. It has a shorter turn-around time than other next-generation 60 sequencing technologies (Petersen et al. 2019; Miller and Chiu 2022) and has been successfully employed 61 to identify viral (Russell et al. 2018; Arévalo et al. 2022), fungal (Ohta et al. 2023) and bacterial agents

62 (Hewitt et al. 2017; Charalampous et al. 2019; Bouchiat et al. 2022). Nanopore sequencing, unlike traditional RT-PCR methods to diagnose viral illness, allows for whole genome sequencing of viruses, 63 64 allowing the identification of viral variants to improve disease surveillance efforts. This was used in the 65 recent COVID-19 pandemic to monitor emerging SARS-CoV-2 variants (Yakovleva et al. 2022; Centers 66 for Disease Control and Prevention 2022). To effectively bring this sequencing to a clinical diagnostic 67 setting, there is a need to effectively validate the use of sequencing assays on clinical samples and 68 develop bioinformatics pipelines that can generate reports that provide clinically actionable insights 69 (Miller et al. 2019).

70 Here, we validate the use of a metagenomic sequencing workflow that rapidly and accurately 71 detects RNA viruses in multiple clinical sample types. This workflow uses unbiased amplification to 72 increase assay sensitivity and multiplexed sequencing to increase throughput and decrease sample 73 analysis cost. Several performance metrics were collected to validate the use of this assay for clinical 74 metagenomics. The limit of detection (LoD) and precision of this assay were determined for seven RNA 75 viruses using contrived samples. We also evaluated the degree to which common contaminants in clinical 76 samples, such as EDTA, interfered with pathogen detection in this workflow. Furthermore, this workflow 77 was tested on commercially purchased remnant clinical samples in addition to contrived samples created 78 in our laboratory, allowing evaluation of assay performance directly against existing clinical assays to 79 determine accuracy.


80

81 **Results**

82 Sample Processing and Bioinformatics Analysis

We developed an untargeted third-generation sequencing assay for RNA virus pathogen identification from nasopharyngeal swabs in viral transport media (VTM) and plasma (Figure 1). This assay includes library preparation, sequencing, and bioinformatics analysis. We then evaluated the performance of the

86 assay using contrived and clinically relevant remnant samples. For each sequencing run, internal 87 sequencing controls consisting of MS2 Phage were spiked into each of the six clinically relevant samples 88 and a NTC ("no template control") of sterile phosphate buffered saline processed in parallel through RNA 89 extraction. Each sequencing run also had a PC (positive control) consisting of an RNA transcript of the 90 gfp gene which was processed through the RNA sequencing library preparation in parallel with the RNA 91 extracted clinically relevant samples and NTC. The sequencing library preparation (Figure 1) for RNA for 92 the untargeted sequencing assay included (1) double-stranded complimentary DNA synthesis (dscDNA 93 synthesis), (2) whole-genome amplification (WGA), (3) ONT native barcoding kit, (4) library pooling in 94 equal molar concentration, (5) ONT ligation sequencing kit, and (6) sequencing on the MinIONTM (Mk1B 95 or Mk1C). Raw reads, 'squiggles' in the fast5 format, were basecalled and demultiplexed either 'live' 96 while sequencing or post-run basecalled using ONT's official 'guppy' basecaller. The resulting 97 demultiplexed and quality filtered reads were analyzed through a bioinformatic pipeline using Epi2Me-98 Labs as a framework. The SigSciDx bioinformatic pipeline consisted of mapping each of the barcoded 99 read bins to the human genomic sequence using 'minimap2' (Li 2021, 2018) to remove human aligned 100 reads. The remaining reads were then mapped to the positive control gene sequence (gfp) and internal 101 sequencing control (MS2 Phage) using 'minimap2' and alignment statistics were generated with 102 'samtools' (Danecek et al. 2021; Li et al. 2009) for assessment of quality of the sequencing run and for 103 the individual samples. The barcoded read bins were also analyzed for taxonomical determination through 104 the 'reference inference' module from SeqScreen. Results from the SigSciDx bioinformatic pipeline were 105 published in a html formatted report for clinician review and interpretation. All remnant samples, positive 106 or negative, were blinded to the analysts performing the extraction and library preparation, and to the 107 analysts performing initial bioinformatic evaluation and interpretation.



109

110

Figure 1. Untargeted sequencing workflow

111

112 Establishing thresholds for reporting detected pathogens

To minimize false-positive results from cross-contamination caused by low-level barcode crosstalk (Xu et al. 2018), we examined the use of ONT's current official basecaller 'guppy' on 1) a setting for single-end barcode binning of reads, requiring detection of only one barcode per sequence read, or 2) both-end barcode binning, requiring matching barcodes are present at both ends of each read. We examined crosstalk from samples in the NTC (Figure 2, Table S1), indicating potential false positives and the loss of sensitivity (Table 1).

1	2	n
1	∠	υ

Table S1. Indication of Barcode Crosstalk by Detection of RNA Virus in TNC

	Media		Vi	ral Tran	sport M	ledia		Human Plasma							
Organism				Hur	nan										
				Respir	ratory	Hun	nan								
0	rgamsm			Sync	ytial	Corona	avirus			Hepat	titis A	Yel	low	Chiku	ngunya
Influe		nza A	Vii	us	229E		Zika Virus		Virus		Fever Virus		Virus		
B	8inning*	S	В	S	В	S	В	S	В	S	В	S	В	S	В
TT: 1 4	А	2/2	0/2	2/2	0/2	2/2	2/2	1/1	1/1	1/1	0/1	1/1	1/1	1/1	1/1
Highest	В	2/2	0/2	2/2	0/2	2/2	1/2	NA	NA	NA	NA	NA	NA	NA	NA
Load	С	0/1	0/1	1/1	0/1	1/1	0/1	2/2	2/2	2/2	0/2	2/2	0/2	2/2	0/2
Levels on Run	D	0/1	0/1	0/1	0/1	0/1	0/1	2/2	0/2	0/2	0/2	2/2	0/2	2/2	0/2
on Kun	Е	NA	NA	NA	NA	NA	NA	1/3	0/3	0/3	0/3	0/3	0/3	2/3	0/3

* S: Single-barcode binning, B: Both-barcode binning

121




Figure 2. Indication of Barcode Crosstalk by Detection of RNA Viruses in NTC of a Run. Percent of RNA viruses detected in contrived samples at different loadings (Table 4) across run using single-end or both-ends demultiplexing methods.

122 Utilizing the both-end barcode binning setting on the basecaller significantly reduced inherent

123 potential false positive calls within the NTC with only a minor reduction in sensitivity of between 0.3 and

- 124 1-Log. Total read counts of binned barcodes reduced crosstalk by 38.9 ± 5.5 % between single-end and
- 125 both-end binning settings.

1	27	
T	21	

Table 1. Comparison of Limit of Detection (LoD) Differences
between Single and Both-end Barcoding Binning

Organism	Both-end	Single-end Barcode	LoD Log
	Barcode Binning	Binning	Differences
Human Respiratory Virus	2.33	1.95	0.38
Influenza A	4.43	4.05	0.38
Human coronavirus 229E	-0.01	NA ^A	NA
Zika Virus	2.74	2.45	0.29
Chikungunya Virus	2.06	1.55	0.51

Yellow Fever Virus	1.88	0.88	1.01				
Hepatitis A Virus	3.12	NA ^A	NA				
A Origination of a finance of the second sec							

Overestimated due to fewer samples at lower load levels

128

129 The sequence analysis results from contrived and remnant clinical samples informed the 130 SigSciDx bioinformatic workflow thresholds as described in the Materials and Methods. This included 131 limiting the number of taxonomical ids initially entering the 'reference inference module' and decreasing 132 the stringency of which reference genomic sequences proceed from the first round of mapping to the 133 second round of mapping within the 'reference inference module'. The criteria for analyst interpretation 134 of detection results were based on replicate sequencing results and inter-run information from contrived 135 and remnant clinical samples, including those from PC, NTC, and internal control. Total number of reads 136 per a barcode with a quality score greater than Q8 was expected to be greater than 40,000. The MinIONTM 137 run was expected to achieve greater than 1.5 million long-reads representing greater than 4 Gb estimated 138 bases with an estimated N50 greater than 2.5 kb, usually 3.5 kb. The minimum number of gfp gene reads 139 in the PC representative barcode must have been greater than 5,000 for a successful run to be considered 140 for further interpretation. MS2 Phage was accessed on two separate criteria based on mapped read count 141 or percentage, depending on which was greater. MS2 Phage in each sample was expected to have mapped 142 greater than 1000 reads, especially in samples with many reads remaining after host removal, or at 50% of 143 the reads remaining after host removal, especially if fewer reads remain after host removal. The NTC and 144 gfp gene barcode samples were used to interpret if high barcode crosstalk or cross-contamination exist. It 145 was expected that only MS2 Phage, or other phages, may be detected within the NTC. If an NTC detected 146 a virus that was also detected in at least one other sample of the run, this dictated a deeper review. 147 Generally, the preferred remedy was determining the sample with a high read count which was positive 148 for the detected virus and re-sequence using the cleaned WGA DNA material of the other samples to 149 verify their positive calls. Otherwise, resequencing all the samples again was also viable. There was little 150 ability to access if a statistical cut-off could be employed such as requiring a 2 or 3 -fold higher number of 151 reads in a sample compared to the NTC for that virus to indicate a detection, as this appeared in only 1 of

- 152 the runs performed on the remnant samples. Further study of remnant or clinical samples could inform a
- 153 statistical required read count in the presence of barcode crosstalk or cross-contamination.

154

155 Limit of Detection

- 156 A 95% limit of detection (LoD) was determined for each of the three and four representative RNA viruses
- 157 in VTM and plasma contrived samples, respectively. We evaluated each RNA virus over a minimum 6-
- Log dilution range, testing 2 to 14 replicates at each concentration. The 95% LoD, defined as the lowest
- 159 concentration at which 95% of positive samples are detected, was determined for each of the seven RNA
- 160 viruses using probit analysis (Table 2).

162

Performance metric	Method	Result					
Limit of detection (LoD)	Qualitative detection of RNA virus dilution replicates by probit analysis	Pathogen Influenza A Virus	LoD (Estimated PFU 26,915 TCID ₅₀ /mL (1				
		Human Respiratory Syncytial Virus	$214 \text{ TCID}_{50}/\text{mL}$ (150				
		Human Coronavirus 229E	1 TCID ₅₀ /mL (1 PFU	/			
		Zika Virus	550 TCID ₅₀ /mL (385				
		Hepatitis A Virus	1318 TCID ₅₀ /mL (92				
		Yellow Fever Virus	68 TCID ₅₀ /mL (47 Pl	FU/ mL)			
		Chikungunya Virus	115 TCID ₅₀ /mL (80 I	PFU/ mL)			
Precision	Qualitative detection over 2 to 7 contrived sample runs of each organism (inter-assay) ²	100 % concordance					
	Qualitative detection of duplicate contrived samples on the same run (intra-assay) ²	100 % concordance					
	Qualitative detection over 21 remnant sample (duplicate or triplicate) runs (inter- assay)	100% concordance					
Interference	Quantitative read count of viruses with spiked blood (5%, 2%)	Decrease of number of reads by 1.3-L	ogs to 1.5-Logs mappe	d to viruses			
	Quantitative read count of viruses with spiked EDTA (100 mM, 10 mM, 5 mM)	Decrease of number of reads by 0.6-Logs and 0.1-Logs with addition of 100 mN and 10 mM EDTA, respectively					
	Quantitative read count of viruses with spiked bacteria (<i>Micrococcus luteus</i> or <i>Staphylococcus epidermidis</i>)	No significant changes in number of r	eads mapped to RNA v	iruses			
Accuracy	18 of single-detection remnant sample runs,						
	results comparisons (3 for each organism).		<u>Sensitivity</u>	Specificity			
		Human metapneumovirus	33.3 [%] ³	100%			
		Parainfluenza IV	33.3%	100%			
		SARS-CoV-2	100%	100%			
		RSV	100%	100%			
		Influenza A	100%	100%			
		Enterovirus	100%	100%			

 Table 2. Performance characteristics for the untargeted sequencing assay

 1 Estimated PFU calculated by multiplying the TCID₅₀ /mL by 0.7 2 Nearest higher loading (Table 4) to that of the LOD (within 1-Log) 3 Includes two of the three samples that did not pass internal control QC

164 **Precision**

165 We demonstrated inter-assay reproducibility of the untargeted sequencing assay by testing of the NTC 166 and contrived samples at the nearest loading above the calculated LoD for each organism across at least 4 167 sequencing runs and intra-assay reproducibility by testing of at least 4 independently generated sets of 168 duplicate contrived samples on the same run (and negative remnant samples in two runs). The gfp gene 169 mRNA transcript positive control passed QC for every completed sequencing run (36 total runs: 20 170 contrived sample runs and 16 remnant sample runs), indicating successful sequencing library generation 171 from cDNA synthesis through sequencing. Internal spiked MS2 phage controls passed QC for all 172 sequenced replicate contrived samples (216 total), indicating conditions across all processes of the 173 workflow were successful, including the RNA extraction process. For remnant samples, 2 samples 174 consistently failed internal spiked phage control QC after 3 independent runs were performed (6 total 175 remnant replicate samples). The remaining 90 of the 96 replicate remnant samples across the 16 runs 176 passed QC for the internal spiked MS2 phage control. The 6 failed internal controls in the replicates of the 177 2 remnant samples occurred in samples that were Human metapneumovirus-positive by original clinical 178 assay and had relative low human sequence contributions compared to the other VTM samples. One of 179 the samples, despite the failed QC, detected the presence of Human metapneumovirus while the other 180 consistently failed to detect. All seven organisms in the contrived samples were detected using pre-181 established threshold criteria for the duplicate intra-assay samples on the same run and each replicate 182 inter-assay run (Table 2). All 9 negative remnant samples, determined to be absent of viral pathogens by 183 previous clinical testing, had no detection by untargeted sequencing of pathogenic RNA viruses within 184 the same run which were divided between 2 individual runs (intra-assay testing). From across all 36 185 sequencing runs (inter-assay testing), 35 NTCs showed no pathogenic RNA virus detections. The single 186 run that showed a positive detection within the NTC, presence of Influenza A, was a remnant run 187 containing a patient sample with a high-load of Influenza A and subsequent two repeats of the run using 188 that sample did not show detection in the NTCs. The read count was at 14 for Influenza A within the NTC

- and had enough coverage and depth to be determined as present despite a lower calculated statistics for
- 190 the mapping. Interpretation was not impacted with the other remnant samples in the run based on pre-
- 191 established interpretation guidelines and criteria.

192 Accuracy

- 193 A total of 31 remnant samples consisting of 18 samples with original clinical positive single detections
- and 13 samples with negative clinical detections were tested using the untargeted sequencing assay.
- 195 Concordance was determined by comparing the assay results to original clinical test results (Table 2 and
- 196 Table S2). Two clinical positive samples failed internal control QC in 3 independent runs. Of the other 16
- 197 clinical positive samples, 13 showed positive concordant detections or true-positives and 3 samples
- 198 showed unexpected negative detections and were classified as false-negatives for detection by the
- 199 untargeted assay. All 13 negative clinical samples were also negative for the untargeted sequencing assay.
- 200

Table S2. Single-detection remnant sample calls

	Ũ	-
Sample	Original Detection Method	Untargeted Sequencing Call
Human Metapneumovirus	Genmark EPlex PCR	Not Detected, Internal Control (IC) Quality
		Control (QC) failed
Human Metapneumovirus	Genmark EPlex PCR	Not Detected
Human Metapneumovirus	Genmark EPlex PCR	Human metapneumovirus, IC QC failed
Parainfluenza IV	Genmark EPlex PCR	Not Detected
Parainfluenza IV	Genmark EPlex PCR	Human parainfluenza virus 4a
Parainfluenza IV	Genmark EPlex PCR	Not Detected
SARS-CoV-2	Gene Xpert Infinity	Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2	Gene Xpert Infinity	Severe acute respiratory syndrome coronavirus 2
SARS-CoV-2	Gene Xpert Infinity	Severe acute respiratory syndrome coronavirus 2
RSV	Biofire	Respiratory syncytial virus
RSV	Biofire	Respiratory syncytial virus
RSV	Biofire	Respiratory syncytial virus
Influenza A	Biofire	Influenza A
Influenza A	Diasorin Integrated Cycler	Influenza A
Influenza A	Biofire	Influenza A
Enterovirus	Diasorin Integrated Cycler	Rhinovirus A1
Enterovirus	Diasorin Integrated Cycler	Rhinovirus A1
Enterovirus	Diasorin Integrated Cycler	Rhinovirus A1

201

202 Overall, the untargeted sequencing assay showed 81.25 % sensitivity (13/16) and 100%

203 specificity (29/29) compared to original clinical positive sample results excluding the internal control QC

204 failures (Table 2). No cases, excluding the internal control QC failed samples, were classified as

- 205 untargeted sequencing assay false positives and two samples originally identified as Parainfluenza IV
- 206 were classified as false negatives; discrepancy testing was not performed.

207 Interference

- 208 We evaluated the effects of interference from blood, EDTA, and increasing additions of *Micrococcus*
- 209 luteus or Staphylococcus epidermidis to contrived plasma samples prior to extraction on the untargeted
- sequencing assay. Exogenous addition of blood to plasma samples at 2% and 5% of the sample prior to
- 211 RNA extraction resulted in a significant 1.34 ± 0.04 -Log and 1.54 ± 0.11 -Log reduction in the number
- of RNA virus reads, respectively (Figure 3) ANCOVA and TukeyHSD, p<0.001). The MS2 Phage
- 213 internal control for the samples indicated only a 0.83-Log reduction in reads (Figure 3).




Figure 3. Interference of RNA virus reads with increasing blood concentration. Number of reads mapped to the individual viruses within contrived samples containing increasing additions of human whole blood.

214




Figure 4. Interference from blood with increasing RNA virus concentration. Number of reads associated with individual viruses at different loading in contrived samples in the presence of 2% blood. Threshold for detection was a minimum of 10 reads leading to absence in graph and subsequent statistical analysis.

The Log reduction in the number of RNA virus reads was also consistent with increasing concentrations of virus within the sample containing 2% blood (Figure 4). The addition of 2% blood to samples with increasing concentrations of viral pathogens had a significant reduction of 1.31 ± 0.05 -Log reads at all pathogen concentrations, with the exception of 'low' pathogen concentrations where the read count dropped below the 10 read threshold and was removed from analysis (ANCOVA and TukeyHSD, p<0.001). The MS2 Phage internal control had only a 0.5-Log reduction in reads with greater variability in the 'high' load viral pathogens in 2% blood.

- 223 Interference caused by the addition of increasing concentration of EDTA was also established
- 224 (Figure 5). The addition of low concentrations of EDTA as sodium salt at 5 mM to the existing
- approximate 4.5 mM potassium EDTA for plasma collection may have increased the extraction efficiency
- of some RNA viruses with an approximate increase in viral reads by 0.3-Log, yet was not statistically




Figure 5. Interference in the presence of EDTA. Number of reads associated with different viruses within contrived samples with increasing concentrations of EDTA.

- significant compared to no EDTA addition (ANCOVA and TukeyHSD, p=0.69). This potential increase
- 228 was eliminated at addition of 10 mM EDTA levels (p=0.99 compared to no addition) and negatively
- impacted RNA virus reads by approximately 0.60 ± 0.13 -Log reduction at additions of 100 mM EDTA
- 230 compared to no addition (p=0.005).
- 231 Finally, we evaluated the addition of *Staphylococcus epidermidis* or *Micrococcus luteus* to known
- 232 positive plasma samples, neither of which negatively impacted viral read counts (Figure 6, ANCOVA:
- 233 p=0.239).




Figure 6. Interference by bacteria addition. Number of reads associated with different viruses in contrived samples with increasing concentrations of *Staphylococcus epidermidis* or *Micrococcus luteus*

235

236

- 238 The relative selectivity of sequences within the different clinical sample matrices, VTM and
- 239 Plasma, and the absence of a complex matrix, NTC, was examined using the MS2 Phage IC used between
- 240 the samples (Figure 7). There was no significant difference in the number of MS2 Phage reads between




Figure 7. Number of MS2 Phage Reads in Different Sample Matrices.

241 the remnant and contrived samples runs (ANCOVA, p=0.537). There was also no significant difference in 242 the number of MS2 Phage reads between the plasma and VTM in either the remnant (TukeyHSD, p=0.18) 243 or contrived (TukeyHSD, p=0.78) runs. The number of MS2 Phage reads in VTM samples had a 244 significant decrease of 1.13 and 1.16-Log compared to NTC (TukeyHSD, p<0.001) in contrived and remnant samples respectively. Plasma had a significant decrease in MS2 Phage reads of 0.92-Log in 245 246 contrived sample runs (TukeHSD, p < 0.001) but not in remnant sample runs (0.68-Log; TukevHSD) 247 p=0.086) compared to NTC. There was no significant difference between the number of human reads 248 between the contrived and remnant samples (ANCOVA, p=0.66) nor between VTM and plasma 249 (ANCOVA, p=0.99). The presence of human reads in the NTC and PC of approximately 300 reads 250 indicates how the majority reads from 6 samples can impact the contamination of reads in samples 251 expected not to contain human reads.

253 Challenge remnant samples

- 254 We evaluated remnant samples containing multiple virus detections by current molecular methods or non-
- 255 overlapping single calls (Table 3). Of the 17 diagnosed viruses present by current molecular diagnostics
- in the 9 samples, 8 of those viruses were confirmed through untargeted sequencing (47%) without
- 257 incorrect identification of other viruses. Discrepancy testing was not performed.
- 258

Table 3. Multiple-detection remnant sample	Table 3	. Multi	ple-de	etection	remnant	sami	oles
--	---------	---------	--------	----------	---------	------	------

Sample	Original Detection Method	Untargeted Sequencing Call					
Human Metapneumovirus	Genmark EPlex PCR	Not Detected					
Rhinovirus		Not Detected					
Parainfluenza IV	Genmark EPlex PCR	Not Detected					
Influenza A		Influenza A					
Human Metapneumovirus	Genmark EPlex PCR	Not Detected					
SARS-CoV-2		SARS-CoV-2					
Human Metapneumovirus	Genmark EPlex PCR	Not Detected					
Parainfluenza IV		Not Detected					
Coronavirus OC43	Biofire	Human coronavirus OC43					
Human Metapneumovirus		Human metapneumovirus					
Parainfluenza II	Biofire	Human orthorubulavirus 2					
Parainfluenza I	Biofire	Not Detected					
Adenovirus	Biofire	Not Detected					
Influenza A		Influenza A					
Parainfluenza III		Simian Agent 10					
Rhinovirus/Enterovirus	Biofire	Not Detected					
Influenza A		Influenza A					

259

260

261 Discussion

262 We have previously developed and evaluated a clinical untargeted sequencing assay intended to aid in the 263 diagnosis of respiratory and blood-borne infections by RNA viruses (Kappell et al. 2023). Here, we 264 rigorously evaluate the best performing of the sequencing methods for different RNA viruses within viral 265 transport media and human plasma through clinically relevant contrived samples and remnant patient 266 samples. We incorporated multiple QC materials, including an external positive control (gfp gene 267 transcript RNA), NTC samples that are run in parallel with clinical samples, and spiked MS2 Phage as an 268 internal process control. Reproducible threshold metrics were established and evaluated to enable 269 identification of pathogens from long-read nanopore sequencing data above background noise and to 270 minimize potential barcode crosstalk within multiplexed analyses. The final sequencing protocol

incorporated: (1) RNA extraction of MS2 Phage spiked samples and NTC, (2) reverse transcription of
RNA into double-stranded cDNA, (3) unbiased amplification through whole genome amplification, (4)
ligation of barcodes and adapters using ONT kits, (5) sequencing, basecalling, and demultiplexing using
ONT MinIONTM (Mk1B or Mk1C), and (6) SigSciDx open-source bioinformatics pipeline for QC and
pathogen detection.

276 Our untargeted sequencing library preparation protocol uses a whole genome amplification 277 (WGA) approach after cDNA synthesis. This step increases assay specificity without requiring targeted 278 amplification. The WGA step has the potential to be further optimized to shorten the time of reaction, but 279 the material generated was sufficient for approximately 3 reactions after a 2-hour incubation, starting with 280 nearly undetectable quantities of cDNA. The amplified material serves as an ideal reference point for 281 additional sequencing or molecular analysis, if needed. WGA was performed using Qiagen REPLI-g kit 282 which has been shown to introduce the lowest amplification bias compared to other multiple displacement 283 amplification (MDA) methods (Pinard et al. 2006) inducing the least distortion in read counts per bin 284 across the length of a genome compared to unamplified controls. While sequencing independent single 285 primer amplification (SISPA) methods are generally quicker than MDA methods, MDA methods are 286 known to perform better than SISPA methods in sequencing output, taxonomic assignments, diversity, 287 and assembly statistics (Kallies et al. 2019; Parras-Moltó et al. 2018). The simplified execution of a MDA 288 based method in the Qiagen kit format has led to our adoption of the method for this untargeted 289 sequencing assay.

290 Contrived VTM and plasma samples in this study that contained 3 and 4 RNA viruses 291 respectively, indicated a range of limits of detection for the untargeted sequencing assay ranging from 1 292 TCID₅₀ /mL (est. 1 PFU/ mL) for Human coronavirus 229E to 26,915 TCID₅₀ /mL (est. 18,840 PFU / 293 mL) for Influenza A virus. Untargeted sequencing assay sensitivity for detection of a given organism is 294 dependent on multiple factors, including extraction efficiency, size of the genome, complexity of the 295 genome, the variability of genomic equivalences (sequenceable material) vs infectious particles, library

296 preparation bias, and availability of matching reference genomes in the database. We think the higher levels of detection for Influenza A are likely due to genome complexity and size. While Influenza A has 297 298 an approximately 13.5 kb genome, it is fragmented into 8 segments ranging in size from 890 to 2.341 bp. 299 The subset of Influenza A genomes available in the NCBI Genbank of complete genomes is also limited, 300 preventing accurate strain level detection. We speculate that Human coronavirus 229E was detected at 301 lower LOD levels due to its large unsegmented 27.5 kb genome allowing multiple targets and ease of 302 progressivity for reverse-transcription and WGA. Another important context of the LOD for the 303 individual viruses used in the study is the variability of genome equivalents infectious particles in a viral 304 stock, similar to particle-to-PFU ratios (Bhat et al. 2022). For example, influenza has a particle-to-PFU ratio of 20-to-50 and SARS-CoV-2 has a range of 10⁴-to-10⁶ for genomic RNA to PFU. As viral stocks 305 306 used for this study were reported in TCID₅₀ related to PFU, correcting for the particle-to-PFU ratio 307 consistent with these values would suggest a more consistent LOD between these viruses.

308 A key limitation for infectious disease diagnostics using untargeted sequencing assays is 309 background interference. The presence of blood as little as 2% volume of the sample led to a greater than 310 10-fold decrease in the number of reads, indicating a potential 1-Log decrease in analytical sensitivity of 311 the assay. This highlights the importance of the plasma capture step from a blood sample during initial 312 sample preparation to maximize assay sensitivity. Additionally, the presence of 100 mM EDTA caused a 313 0.6-Log reduction in reads and potential loss in analytical sensitivity. The presence of such an excess of 314 EDTA is unlikely, but a low volume of blood captured in a K₂-EDTA vacutainer tube would increase the 315 concentration of EDTA present in the extracted sample could be indicated as a potential cause for 316 sequencing failure. The spiked MS2 phage IC was useful for assessing the decreased assay sensitivity 317 caused by interferents or due to matrix effects. Notably, matrix effects on read counts from the MS2 318 Phage IC were more variable in the remnant samples compared to the NTC. While these matrix effects 319 had an impact on total read output, the read count following host removal was most noteworthy. Remnant 320 samples that had fewer mapped MS2 reads following host removal typically showed fewer or no

321 pathogen reads. This indicated potential interference from high human background or potentially other 322 confounding inhibitors. Accordingly, repeated failures or low read abundance of the MS2 Phage IC may 323 indicate poor assay performance. In this case, other diagnostic tests that are less sensitive to interference 324 should be considered (e.g., RT-PCR).

325 Of the 35 RNA viruses detected by conventional clinical molecular assays across 27 total remnant 326 samples, untargeted sequencing detected 22 concordant positives. Concordant negative detections 327 occurred in 13 out of 13 negative remnant samples. These findings show the unbiased sequencing assay 328 has 62.9% sensitivity and 100% specificity. The calculated 62.9% sensitivity refers to clinical sensitivity 329 in diagnosis of infection and not analytical sensitivity or detection of pathogen nucleic acid. Multiple 330 factors likely play a role in limiting the clinical sensitivity of untargeted sequencing, including: (1) the use 331 of remnant samples as a "gold standard", with the potential that some samples may represent false 332 positives due to PCR artifacts or incorrect handling (e.g., contamination), (2) the potential that remnant 333 samples have undergone nucleic acid degradation from prior freeze-thaw steps, (3) the necessary use of 334 both-end barcode demultiplexing and robust pre-established thresholds to minimize false-positive 335 detections that could filter appropriate pathogen sequencing data, and (5) potential patient medications, 336 treatments, or other interferents that cause assay inhibition. Discrepancy testing was not performed to 337 determine the potential causes for the false-negative cases.

338 Approximately 14 of the 40 total remnant samples used in this study, including negative remnant 339 samples, had additional virus species or genera detected above pre-established thresholds consisting of 340 environmental or normal flora. Most of the additional detections were of phage, most likely due to the 341 mappings of the MS2 Phage to additional phage sequences and small amounts of contamination in 342 workflow reagents. Torque teno viruses, Torque teno midi virus, and TTV-like mini viruses were also 343 identified in several of the remnant VTM samples. These anelloviruses have small circular, negative-344 sense, single-stranded DNA genomes which may have escaped the DNA removal column-based step in 345 the RNA extraction process. These anelloviruses are not directly concerning as they are diverse and

346 commensal members of the human virome (Bendinelli and Maggi 2010). However, their increase leading 347 to detection may indicate host immunosuppression (del Rosal et al. 2023; Prasetyo et al. 2015). 348 Determining the clinical significance of detecting viruses that may be contaminants or normal flora 349 remains a classical problem in clinical microbiology and often requires clinical context for interpretation. 350 While plasma is normally a sterile sample, manipulation and handling of the sample may introduce low 351 levels of contamination which ultimately gets amplified by our use of WGA within the untargeted 352 sequencing protocol. Additionally, the collection using nasopharyngeal swabs into VTM in a non-sterile 353 site collection environment presents a reasonable risk of several potential environmental and normal flora 354 being captured along with viral pathogens. Thus, detection of multiple viruses as potential contamination 355 or normal flora were noted and were considered negative in our evaluation of assay performance. 356 Untargeted sequencing testing can provide broad-spectrum RNA virus detection and 357 identification, however assessment of the clinical significance of the reported findings may require 358 interpretation. Clinical context of the results from untargeted sequencing is important in discussing and 359 reviewing patient cases with the treating clinicians. The potential for untargeted sequencing for RNA 360 virus identification includes characterization of antiviral or vaccination escape mutations, genotyping or 361 strain-level identification, and presence of reads from potential pathogens below formal threshold that can 362 inform follow-up targeted testing.

363

364 Methods

365 Remnant Clinical Samples

Clinically diagnosed, de-identified remnant samples were obtained from Discovery Life Sciences and Precision for Medicine. Of the 40 remnant samples evaluated, 9 VTM samples were negative based on molecular respiratory panels, 4 were negative serum or plasma samples, and 27 VTM samples were positive for single or multiple respiratory viruses. Of the remnant samples, 6 different RNA virus

370	pathogens as determined by standard clinical testing were represented by 3 samples each. These 18
371	remnant VTM samples were used for the initial accuracy study. The other 9 VTM samples containing
372	mixed or singlet samples with one diagnosed pathogen were kept for additional challenge samples.
373	Remnant samples were pipetted into 140 μ L single use aliquots for extraction. The number of prior freeze
374	thaws of remnant samples was unknown before receipt. Samples were stored at -80 °C upon receipt and
375	again after aliquots were prepared.
376	Contrived Sample Preparation
376 377	Contrived Sample Preparation Aliquots of negative diagnosed remnant VTM or plasma were pooled to generate a matrix for contrived
377	Aliquots of negative diagnosed remnant VTM or plasma were pooled to generate a matrix for contrived
377 378	Aliquots of negative diagnosed remnant VTM or plasma were pooled to generate a matrix for contrived RNA virus samples. Contrived samples in VTM were prepared using Influenza A virus (BEI Resources

382 (BEI Resources NR-50065). To determine LoD, contrived samples were prepared at a starting dilution of

383 25 μL/mL stock material in pooled VTM or plasma. Tenfold serial dilutions were prepared in respective

384 pre-screened negative matrices to a final concentration of 0.00025 µL/mL. The viral load levels in

385 TCID₅₀/ mL at the different serial dilutions are indicated in Table 4. All samples were prepared into single

use 140 μL sample aliquots and frozen at -80 °C until extraction.

387

Table 4 Contrived Sample Loading

	Media:	Viral	Viral Transport Media			Human Plasma			
	Virus:	Influenza A Virus (A/Wisconsin/15/ 2009 (H3N2)	Human Respiratory Syncytial Virus (A 1998/ 3-2)	Human Coronavirus (229E)	Zika Virus (MR 766)	Hepatitis A Virus (HM175/18f)	Yellow Fever Virus (17D)	Chikungunya Virus (181/25)	
					NR-				
	BEI Cat#	NR-42007	NR-28529	NR-52726	50065	NR-137	NR-116	NR-56523	
x /· 1	A*	7.10	5.60	3.85	7.35	6.85	6.60	6.35	
Viral	В	6.10	4.60	2.85	6.35	5.85	5.60	5.35	
Load	С	5.10	3.60	1.85	5.35	4.85	4.60	4.35	
Levels	D	4.10	2.60	0.85	4.35	3.85	3.60	3.35	
Log ₁₀ (TCID ₅₀ /	Е	3.10	1.60	-0.15	3.35	2.85	2.60	2.35	
$(1CID_{50}/mL)$	F	2.10	0.60	-1.15	2.35	1.85	1.60	1.35	
111L)	G	NA	NA	NA	1.35	0.85	0.60	0.35	

*The letters in column 1 provide a designation for the specific viral load of each virus in the corresponding row. Viral loads decrease as the letters continue, with "A" representing the highest load level.

388

389 Untargeted Third-Generation Sequencing

390 RNA from contrived and remnant clinical samples was extracted using the Oiagen RNeasy Plus Micro 391 Kit (Qiagen #74034) with minor changes to the manufacturer's standard protocol adapting to the specific 392 sample matrix and input volume of 140 μ L sample material augmented with 5 μ L of MS2 Phage internal 393 control (ZeptoMetrix, 0810274; 145 µL total input). Extracted RNA was immediately reverse-transcribed 394 using random hexamers and Maxima H Minus Double-Stranded cDNA Synthesis Kit (Thermofisher 395 K2561) following manufacturer's instructions including the recommended changes to increase the 396 addition of 1st strand enzyme mix to 2 µL and the incubation temperature to 55 °C. In addition to the 397 extracted RNA, an RNA transcript of the gfp gene (System Biosciences, LLC MR700A-1) was included 398 as an additional positive control sample at 6 pg. If necessary, DNA forms of samples were stored at -20 399 °C only after bead clean-up of the previous reaction steps. Double-stranded cDNA was cleaned using 400 AMPure XP beads before whole genome replication using the Qiagen REPLI-g Advanced DNA Single 401 Cell Kit (Qiagen, 150363) following the Qiagen supplementary protocol "Whole genome amplification 402 from genomic DNA using the REPLI-g Advanced DNA Single Cell Kit with increased sample volumes." 403 Briefly, 15 μ L of double-stranded cDNA was denatured with 2 μ L of Advanced Buffer DLB for 3 404 minutes at 25 °C. Stop Solution was added at 3 µL and mixed. The 29 µL REPLI-g sc Advanced Reaction 405 Buffer with 2 µL REPLI-g sc DNA Polymerase was added directly to the denatured cDNA and incubated 406 for 2 hours at 30 °C. The REPLI-g sc DNA polymerase was inactivated at 65 °C for 3 minutes. The 407 resulting amplified DNA was purified from the reaction by AMPure XP bead clean up and digested using 408 T7 Endonuclease I (New England Biolabs (NEB), M0302L). For effective removal of T7 digested 409 fragments, a custom AMPure XP bead solution was made using PEG 8000 50% (w/v) (Fisher Scientific, 410 NC1017553) as described in Oxford Nanopore Technology's (ONT) whole genome amplification 411 protocol for LSK110 (v110, rev. 10 Nov 2020, Oxford Nanopore Technologies 2023). Once purified, the 412 sequencing library was prepared by using end repair and ligation following the ONT's protocol for the

413 Ligation sequencing kit (SQK-LSK110). Native barcode expansion kit 1-12 (EXP-NBD104) was used for 414 multiplexing samples. All bead cleanups were done on a microfuge tube magnetic separation stand (Permagen). Sequencing was performed on Oxford Nanopore Technologies MinIONTM Mk1B or Mk1C 415 416 using R9.4.1 flow cells (FLO-MIN106D). Each flow cell was primed and loaded using manufacturer's 417 instructions. Each run used 24-hour run default settings except no reserve pores. 'Live' basecalling was 418 performed in 'Fast basecalling mode' and single-end barcode demultiplexing. The 'live' basecalling was 419 performed with the latest MinKNOW (22.12.5 to 23.04.03) running the Mk1C or Mk1B which did not impact 'Fast basecalling' (guppy 6.4.6 - 6.5.7) based on change logs and no changes on re-basecalling of 420 421 the earliest run. Alternative basecalling and demultiplexing including both-end barcode demultiplexing of the sequencing runs were performed using standalone 'guppy' basecaller version 6.2.1. All data analyzed 422 423 was basecalled with version 6.2.1 in both-end barcode demultiplexing as a final workflow, with the 424 exception for initial comparison of single-end and double-end barcode demultiplexing (Figure 2, Table 1).

425 **Bioinformatics Analysis**

426 Analyses were developed using EPI2ME Labs (https://github.com/epi2me-labs), a Jupyter-notebook 427 platform allowing users to run pre-written python, R, or BASH based analyses in a web-browser based 428 environment. For each sequencing run, passing reads (default Q8 threshold) were concatenated for each 429 barcode, and quality of run statistics (e.g., read length and quality distribution) were reported and 430 visualized in the web-based environment. Human reads were removed and reported after mapping to the 431 human genome using 'minimap2' (Li 2021, 2018) with default 'ont' parameters. The remaining human 432 depleted reads were then mapped to the control sequences of the gfp gene and MS2 Phage internal 433 controls using minimap2, while removing the gfp mapped reads. The number and percentage of reads 434 aligned to the human genome, gfp gene, and MS2 Phage were analyzed using SAMtools (Danecek et al. 435 2021; Li et al. 2009) and reported in the Quality Control (QC) portion of the output for review. 436 Untargeted sequence analysis was performed using Centrifuge (Kim et al. 2016) with a customized virus

database to identify putative NCBI taxonomy identifiers (taxids) and input those taxids into the 'reference
inference module' of SeqScreen-Nano (Balaji et al. 2023b, 2023a).

439 The customized Centrifuge database is formed of the 'Complete Genome' or 'Chromosome' from the 440 viral genomes from NCBI's GenBank database, excluding all partial or incomplete genome sequences, 441 using the centrifuge-download command. The centrifuge-build command was used as described by 442 Centrifuge developers (Centrifuge Developers 2023; Kim et al. 2016) to generate the custom virus 443 sequence database to use with the Centrifuge taxonomical classifier. The taxids reported by Centrifuge 444 were filtered to include only those taxids with greater than 10 reads assigned to a species or leaf 445 taxonomical level. The 'reference inference module' from SeqScreen-Nano (SeqScreen version 4.0) then used the filtered taxids from the Centrifuge to download the corresponding reference genomes from 446 447 NCBI. All reads were then independently mapped using 'minimap2' to each of those individual reference 448 genomes, and mapping metrics (e.g., depth, breadth of coverage) were calculated by SeqScreen-Nano. 449 High-coverage reference genomes were concatenated by SeqScreen-Nano's 'reference inference module' 450 before the second alignment step, where the reads were remapped to the concatenated reference to allow 451 each read to competitively map to the single best reference. Mapping metrics were re-calculated and 452 further statistical analysis was performed to determine the likelihood of presence or absence of individual 453 genomes based on a rubric. The SeqScreen-Nano 'reference inference module' analysis, metrics, and 454 rubrics are originally described in Balaji et al. (2023a). Modification to the threshold criteria was made to 455 be more inclusive of the reference genomes taken from the first mapping of individual reference genomes 456 to the second mapping of a concatenated reference. This included reducing the original calculated in 457 SeqScreen-Nano 'coverage score' threshold, which is the ratio of the observed 'breadth of coverage' and 458 'expected breadth of coverage' for each taxon in a sample (Balaji et al. 2023a), from a minimum of 0.70 459 to 0.10. The large ratio of 0.7 for the 'coverage score' was not ideal for smaller genomes for viruses, 460 which had inflated expected coverages compared to genomes sizes of bacteria. This allowed for more 461 reference viral genomes within the sample to be used in second stage mapping, while still removing

462	potential contaminants. Additionally, signals from low abundance or partially covered genomes of close
463	neighboring viral taxons were successfully reduced by requiring a greater than 0.15 'breadth of coverage'
464	for a reference genome to move forward in the second stage of mapping. These changes increased the
465	inclusion of viral genomes known to be present within a sample while also reducing background and
466	known contamination. The rubrics within SeqScreen v4.0 for "Present" (Species) and "Genus Present"
467	calls were not modified.

468

469 Evaluation of Untargeted Sequencing and Analysis

470 Statistical analysis and visualizations were performed using R version 4.3.1 (R Core Team 2023)

471 and RStudio version 2023.06.01.524 (Posit team 2023). Visualization of the data was performed using the

472 'ggplot2' R package (Wickham 2016).

Limits of detection were determined for each of the seven representative RNA viruses in their respective clinical matrices by probit analysis using a series of dilutions across a minimum of 6-Log range (Table 4). The contrived samples in the plasma matrix were sequenced across a total of 8 multiplex runs and samples in VTM were sequenced across a total of 6 multiplex runs. Assay LoD were calculated in R and RStudio using probit regression model using the 'glm', generalized linear model, function as the concentration at which RNA virus was detected in 95% of replicates with at least 2 samples performed at each tested concentration (Table S3).

480

Load Level	Plasma	VTM
(See Table 5)		
Α	2	4
В	2	8
C	6	10
D	8	8
E	14	4
F	10	2
G	6	NA

Table S3. Number of contrived samples at virus load sequenced

482	Precision was determined using repeat analysis of the contrived samples for RNA viruses at the
483	load above and nearest their individual LoD as determined by probit analysis (LoD load) across 4 or 5
484	runs with VTM contrived samples and 4 or 7 runs with plasma contrived samples for inter-assay
485	reproducibility. Precision was also determined using repeat analysis of NTC samples across all 14 runs
486	for inter-assay reproducibility. Replicate remnant samples were also used for inter-assay reproducibility
487	ranging from 2 to 3 independent runs performed for each sample performed across a total of 16 runs.
488	Precision for intra-assay reproducibility was determined for each individual RNA virus for duplicate
489	contrived samples at LoD load performed on 4 to 7 runs. Intra-assay reproducibility was also determined
490	for negative detection remnant samples representing 3 (plasma/serum) or all 6 (VTM) samples across a
491	total of 2 runs.
492	Accuracy was determined using 24 remnant VTM samples comprised of 18 positive samples
493	containing 6 detected organisms (three samples for each organism) and 6 negative samples. Sensitivity
494	and specificity of the untargeted sequencing assay were calculated relative to prior 'gold standard' clinical
495	molecular method, which was information provided with the obtained remnant samples.
496	To evaluate the effects of potential interfering substances, EDTA, human blood, and microbial
497	contamination simulated by Micrococcus luteus or Staphylococcus epidermidis were added to contrived
498	plasma samples. The addition of interfering substances was performed on plasma samples with RNA viral
499	load level E (Table 4). EDTA was added to an additional 5 mM, 10 mM, and 100 mM EDTA disodium
500	salt to the plasma samples prior to RNA extraction and downstream workflow. Blood was added to
501	represent 2% or 5% of the total volume of the plasma sample. Additional analysis of the effects of human
502	blood on the untargeted sequencing assay was performed on plasma samples with RNA virus loads of D,
503	E, and F with the addition of 2% blood. For addition of Micrococcus luteus or Staphylococcus
504	epidermidis, an overnight culture was washed twice with sterile molecular grade water. The cells were
505	resuspended at high concentration and quantified by OD ₆₀₀ . The bacteria were added to contrived plasma
506	samples to generate bacterial concentrations at 107 (high), 106 (medium), and 105 (low) cells per mL. The

507	number of reads were determined by the Centrifuge results mapping to the individual RNA viruses. The
508	read counts were normalized by each organism prior to performing ANCOVA in R to determine if
509	significant differences existed between the concentration of interfering substances and no addition. Post-
510	hoc comparisons between the concentration and no addition were made using TukeyHSD (honestly
511	significant difference) testing.
512	An additional examination of remnant samples containing multiple viral detections or single
513	sample representatives of a virus was performed. These 9 samples represented 10 different viruses and
514	were sequenced using the untargeted sequencing assay and concordance with 'gold standard' clinical
515	molecular testing was examined.
516	Software availability
517	The "SigSciDx" computational software used in this study, along with the custom Centrifuge database, is
518	publicly available as the following docker image on Docker Hub: sigsci/sigscidx (Signature Science
519	Team 2023b). The version used for analysis in this publication is 1.0.1. A bash command to initiate the
520	EPI2ME Labs framework is available on GitHub (Signature Science Team 2023c). Note that the database
521	used for the custom viral Centrifuge database was from the June 2023 distribution of GenBank genome
522	assemblies.
523	Data Access

Metagenomic reads from contrived and remnant samples from this study were depleted of human host sequences and will be submitted to the NCBI BioProject database (Signature Science Team 2023a). The MS2 Phage genome sequence used was NC001417.2 for mapping. The *gfp* gene sequence used for mapping was obtained through direct communication with the vendor, System Biosciences, LLC (MR700A-1). Both MS2 Phage and *gfp* gene sequences from the specific vendors are included in the SigSciDx docker image.

530 Competing interests

531 The authors declare that they have no competing interests.

532 Acknowledgements

- 533 The authors would like to thank Leslie Parke for oversight and project management for this effort. The
- authors would also like to thank Jim Gibson for his assistance creating the workflow figure. The authors
- 535 would also like to thank Leslie Parke for her review. This work was supported by the Centers for Disease
- 536 Control and Prevention under contract number 75D30122C15359.

537 Authors' contributions

- 538 All authors have read and approved the manuscript. Conceptualization: ADK, KQS, MBS, FCH. Data
- 539 curation: ADK, MBS, NCK. Laboratory analysis: ANS, NCK, KQS, EAS, CJS, ADK, LWA, TAW.
- 540 Funding acquisition: ADK, FCH, KLT, KQS. Data analysis: ADK, MBS, NCK, KLT, FCH. Project
- 541 administration: ADK, FCH. Writing original draft: ADK, NCK, MBS, KQS, VMJ, FCH, KLT. Writing
- 542 review & editing: ADK, KQS, MBS, LWA, KLT, FCH.

543 References

544	Arévalo MT, Karavis MA, Katoski SE, Harris JV, Hill JM, Deshpande SV, Roth PA, Liem AT,
545	Bernhards RC. 2022. A Rapid, Whole Genome Sequencing Assay for Detection and
546	Characterization of Novel Coronavirus (SARS-CoV-2) Clinical Specimens Using Nanopore
547	Sequencing. Front Microbiol 13. https://www.frontiersin.org/articles/10.3389/fmicb.2022.910955
548	(Accessed September 8, 2023).
549	Balaji A, Liu Y, Nute MG, Hu B, Kappell A, LeSassier DS, Godbold GD, Ternus KL, Treangen TJ.
550	2023a. SeqScreen-Nano: a computational platform for rapid, in-field characterization of
551	previously unseen pathogens. 2023.02.10.528096.
552	https://www.biorxiv.org/content/10.1101/2023.02.10.528096v2 (Accessed September 7, 2023).

- Balaji A, Liu Y, Nute MG, Treangen TJ. 2023b. SeqScreen's reference inference module.
 https://gitlab.com/treangenlab/seqscreen/-/blob/master/scripts/reference_inference.py.
- Bendinelli M, Maggi F. 2010. TT Virus and Other Anelloviruses. In *Topley & Wilson's Microbiology and Microbial Infections*, John Wiley & Sons, Ltd
 https://onlinelibrary.wiley.com/doi/abs/10.1002/9780470688618.taw0263 (Accessed September
 7, 2023).
- 559 Bhat T, Cao A, Yin J. 2022. Virus-like Particles: Measures and Biological Functions. *Viruses* 14: 383.

560	Bibby K. 2013. Metagenomic identification of viral pathogens. Trends Biotechnol 31: 275–279.
561 562 563 564	 Bouchiat C, Ginevra C, Benito Y, Gaillard T, Salord H, Dauwalder O, Laurent F, Vandenesch F. 2022. Improving the Diagnosis of Bacterial Infections: Evaluation of 16S rRNA Nanopore Metagenomics in Culture-Negative Samples. <i>Front Microbiol</i> 13. https://www.frontiersin.org/articles/10.3389/fmicb.2022.943441 (Accessed September 8, 2023).
565	Centers for Disease Control and Prevention. 2022. SARS-CoV-2 Sequencing Resources.
566	https://github.com/CDCgov/SARS-CoV-2_Sequencing (Accessed August 22, 2022).
567	Centrifuge Developers. 2023. Manual for Centrifuge, Database download and index building.
568	https://ccb.jhu.edu/software/centrifuge/manual.shtml#database-download-and-index-building.
569	Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S, Turner DJ,
570	Wain J, et al. 2019. Nanopore metagenomics enables rapid clinical diagnosis of bacterial lower
571	respiratory infection. <i>Nat Biotechnol</i> 37: 783–792.
572 573	Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, Whitwham A, Keane T, McCarthy SA, Davies RM, et al. 2021. Twelve years of SAMtools and BCFtools. <i>GigaScience</i> 10 : giab008.
574	del Rosal T, García-García ML, Casas I, Iglesias-Caballero M, Pozo F, Alcolea S, Bravo B, Rodrigo-
575	Muñoz JM, del Pozo V, Calvo C. 2023. Torque Teno Virus in Nasopharyngeal Aspirate of
576	Children With Viral Respiratory Infections. <i>Pediatr Infect Dis J</i> 42: 184.
577	Fendrick AM, Monto AS, Nightengale B, Sarnes M. 2003. The Economic Burden of Non–Influenza-
578	Related Viral Respiratory Tract Infection in the United States. <i>Arch Intern Med</i> 163: 487–494.
579	Hewitt FC, Guertin SL, Ternus KL, Schulte K, Kadavy DR. 2017. Toward Rapid Sequenced-Based
580	Detection and Characterization of Causative Agents of Bacteremia. 162735.
581	https://www.biorxiv.org/content/10.1101/162735v1 (Accessed August 22, 2022).
582	Kallies R, Hölzer M, Brizola Toscan R, Nunes da Rocha U, Anders J, Marz M, Chatzinotas A. 2019.
583	Evaluation of Sequencing Library Preparation Protocols for Viral Metagenomic Analysis from
584	Pristine Aquifer Groundwaters. <i>Viruses</i> 11: 484.
585	Kappell AD, Scholes AN, Scholz MB, Keplinger NC, Allen LW, Murray MC, Ternus KL, Hewitt FC.
586	2023. Unbiased metagenomic detection of RNA viruses for rapid identification of viral pathogens
587	in clinical samples. <i>Prepration</i> .
588 589	Kim D, Song L, Breitwieser FP, Salzberg SL. 2016. Centrifuge: rapid and sensitive classification of metagenomic sequences. <i>Genome Res</i> 26 : 1721–1729.
590	Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. <i>Bioinformatics</i> 34 : 3094–3100.
591	Li H. 2021. New strategies to improve minimap2 alignment accuracy. <i>Bioinformatics</i> 37 : 4572–4574.
592 593	Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. <i>Bioinforma Oxf Engl</i> 25 : 2078–9.
594 595	Miller RR, Montoya V, Gardy JL, Patrick DM, Tang P. 2013. Metagenomics for pathogen detection in public health. <i>Genome Med</i> 5 : 81.

- Miller S, Chiu C. 2022. The Role of Metagenomics and Next-Generation Sequencing in Infectious
 Disease Diagnosis. *Clin Chem* 68: 115–124.
- Miller S, Naccache SN, Samayoa E, Messacar K, Arevalo S, Federman S, Stryke D, Pham E, Fung B,
 Bolosky WJ, et al. 2019. Laboratory validation of a clinical metagenomic sequencing assay for
 pathogen detection in cerebrospinal fluid. *Genome Res* 29: 831–842.
- 601 Ohta A, Nishi K, Hirota K, Matsuo Y. 2023. Using nanopore sequencing to identify fungi from clinical
 602 samples with high phylogenetic resolution. *Sci Rep* 13: 9785.

603Oxford Nanopore Technologies. 2023. LIGATION SEQUENCING GDNA - WHOLE GENOME604AMPLIFICATION (SQK-LSK110).

- 605https://community.nanoporetech.com/docs/prepare/library_prep_protocols/premium-whole-606genome-amplification-sqk-lsk110/v/wal_9115_v110_revh_10nov2020/whole-genome-607amplification.
- Parras-Moltó M, Rodríguez-Galet A, Suárez-Rodríguez P, López-Bueno A. 2018. Evaluation of bias
 induced by viral enrichment and random amplification protocols in metagenomic surveys of
 saliva DNA viruses. *Microbiome* 6: 119.
- Petersen LM, Martin IW, Moschetti WE, Kershaw CM, Tsongalis GJ. 2019. Third-Generation
 Sequencing in the Clinical Laboratory: Exploring the Advantages and Challenges of Nanopore
 Sequencing. J Clin Microbiol 58: 10.1128/jcm.01315-19.
- Pinard R, de Winter A, Sarkis GJ, Gerstein MB, Tartaro KR, Plant RN, Egholm M, Rothberg JM,
 Leamon JH. 2006. Assessment of whole genome amplification-induced bias through highthroughput, massively parallel whole genome sequencing. *BMC Genomics* 7: 216.
- 617 Posit team. 2023. RStudio: Integrated Development Environment for R. http://www.posit.co/.
- Prasetyo AA, Desyardi MN, Tanamas J, Suradi, Reviono, Harsini, Kageyama S, Chikumi H, Shimizu E.
 2015. Respiratory Viruses and Torque Teno Virus in Adults with Acute Respiratory Infections.
 Intervirology 58: 57–68.
- R Core Team. 2023. R: A Language and Environment for Statistical Computing. https://www.R project.org/.
- Russell JA, Campos B, Stone J, Blosser EM, Burkett-Cadena N, Jacobs JL. 2018. Unbiased Strain-Typing
 of Arbovirus Directly from Mosquitoes Using Nanopore Sequencing: A Field-forward
 Biosurveillance Protocol. *Sci Rep* 8: 5417.
- Schlaberg R, Chiu CY, Miller S, Procop GW, Weinstock G, the Professional Practice Committee and
 Committee on Laboratory Practices of the American Society for Microbiology, the Microbiology
 Resource Committee of the College of American Pathologists. 2017. Validation of Metagenomic
 Next-Generation Sequencing Tests for Universal Pathogen Detection. *Arch Pathol Lab Med* 141:
 776–786.
- 631 Signature Science Team. 2023a. NCBI BioProject Database Respository.
- 632 https://www.ncbi.nlm.nih.gov/bioproject.

633	Signature Science Team. 2023b. SigSciDx.
634	https://hub.docker.com/repository/docker/sigsci/sigscidx/general.
635	Signature Science Team. 2023c. SigSciDx Docker Start Command.
636	https://github.com/signaturescience/lrn_linux_epi2me_start.
637	Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. 2004. Influenza-
638	Associated Hospitalizations in the United States. <i>JAMA</i> 292 : 1333–1340.
639	Wickham H. 2016. <i>ggplot2</i> . Springer International Publishing, Cham
640	http://link.springer.com/10.1007/978-3-319-24277-4 (Accessed September 7, 2023).
641 642 643	 Xu Y, Lewandowski K, Lumley S, Pullan S, Vipond R, Carroll M, Foster D, Matthews PC, Peto T, Crook D. 2018. Detection of Viral Pathogens With Multiplex Nanopore MinION Sequencing: Be Careful With Cross-Talk. <i>Front Microbiol</i> 9: 2225.
644 645 646	Yakovleva A, Kovalenko G, Redlinger M, Liulchuk MG, Bortz E, Zadorozhna VI, Scherbinska AM, Wertheim JO, Goodfellow I, Meredith L, et al. 2022. Tracking SARS-COV-2 variants using Nanopore sequencing in Ukraine in 2021. <i>Sci Rep</i> 12 : 15749.
647 648	Young-Xu Y, Aalst R van, Russo E, Lee JKH, Chit A. 2017. The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population. <i>PLOS ONE</i> 12 : e0169344.